MX2022000889A - Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. - Google Patents

Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.

Info

Publication number
MX2022000889A
MX2022000889A MX2022000889A MX2022000889A MX2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A MX 2022000889 A MX2022000889 A MX 2022000889A
Authority
MX
Mexico
Prior art keywords
hydroxybenzoyl
egf
amino
salt
caprylic acid
Prior art date
Application number
MX2022000889A
Other languages
English (en)
Inventor
Andreas Vegge
Betty Lomstein Pedersen
Birgitte Nissen
Kaisa Naelapää
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022000889A publication Critical patent/MX2022000889A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden un inhibidor de PCSK9, tal como un péptido de EGF(A), y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de las composiciones, y a su uso en medicina.
MX2022000889A 2019-08-07 2020-08-07 Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. MX2022000889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190506 2019-08-07
PCT/EP2020/072227 WO2021023855A1 (en) 2019-08-07 2020-08-07 Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
MX2022000889A true MX2022000889A (es) 2022-02-14

Family

ID=67551283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000889A MX2022000889A (es) 2019-08-07 2020-08-07 Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.

Country Status (14)

Country Link
US (1) US20220323544A1 (es)
EP (1) EP4009958A1 (es)
KR (1) KR20220046565A (es)
CN (1) CN114222581A (es)
AR (1) AR122299A1 (es)
AU (1) AU2020326265A1 (es)
BR (1) BR112022000529A2 (es)
CA (1) CA3144618A1 (es)
CO (1) CO2022000575A2 (es)
IL (1) IL289505A (es)
MX (1) MX2022000889A (es)
PE (1) PE20220486A1 (es)
TW (1) TW202120118A (es)
WO (1) WO2021023855A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240036563A (ko) * 2021-07-15 2024-03-20 노보 노르디스크 에이/에스 N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CA2837658A1 (en) 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
ES2965469T3 (es) * 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
HRP20220720T1 (hr) 2016-01-13 2022-09-30 Novo Nordisk A/S Analozi egf(a) s masnim kiselinama kao supstituentima
EP3474875A1 (en) * 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Compositions and methods for treating cardiovascular disease
US20200165313A1 (en) 2017-07-19 2020-05-28 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof

Also Published As

Publication number Publication date
AU2020326265A1 (en) 2022-02-03
AR122299A1 (es) 2022-08-31
BR112022000529A2 (pt) 2022-03-03
PE20220486A1 (es) 2022-04-04
CO2022000575A2 (es) 2022-04-29
EP4009958A1 (en) 2022-06-15
CN114222581A (zh) 2022-03-22
WO2021023855A1 (en) 2021-02-11
KR20220046565A (ko) 2022-04-14
IL289505A (en) 2022-02-01
TW202120118A (zh) 2021-06-01
CA3144618A1 (en) 2021-02-11
US20220323544A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
MX2022000827A (es) Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2022004718A (es) Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2013006171A (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX341324B (es) Polipeptidos.
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
MX2022000889A (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
WO2015086686A3 (en) Protease resistant peptides
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
GB2556854A (en) Cosmetic formulations
MX2021008748A (es) Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.
CO2024000581A2 (es) Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
JOP20220097A1 (ar) كريزانليزوماب يحتوي على صياغات اجسام مضادة